Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in The Netherlands

American Journal of Cardiology - Tập 65 - Trang 27-32 - 1990
Leon L. Martens1,2,3,4, Frans F.H. Rutten1,2,3,4, D.William Erkelens1,2,3,4, Carl A.P.L. Ascoop1,2,3,4
1From the Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
2From the Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands/University of Limburg, Maastricht, The Netherlands
3From the Department of Internal Medicine, University Hospital Utrecht, The Netherlands
4From the Sint Antonius Hospital, Nieuwegein, The Netherlands

Tài liệu tham khảo

Lipid Research Clinics Program, 1984, The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025 Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 1988, A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia, JAMA, 260, 359, 10.1001/jama.1988.03410030075032 Tobert, 1988, Efficacy and long-term adverse effect pattern of lovastatin, Am J Cardiol, 62, 1J, 10.1016/0002-9149(88)90004-5 1987, Hart Bull (suppl), 1, 3 Martens, 1989, Cost effectiveness of cholesterol-lowering therapy in The Netherlands: simvastatin versus cholestyramine, Am J Med, 87, 54S, 10.1016/S0002-9343(89)80600-X Lipid Research Clinics Program, 1984, The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol-lowering, JAMA, 251, 365, 10.1001/jama.1984.03340270043026 Marketing Authorization Application for Zocor (simvastatin). Data on file at Merck Sharp & Dohme Research Laboratories, Blue Bell, PA, and at the Food and Drug Administration, Washington, D.C. Martin, 1986, Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men, Lancet, 2, 933, 10.1016/S0140-6736(86)90597-0 Maas, 1987, De kosten en effecten van bevolkingsonderzoek op borstkanker Martens, 1990, Dealing with discounting: an application to the cost-effectiveness of intra-coronary thrombolysis with streptokinase, Int J Tech Assess Hlth Care, 10.1017/S0266462300008990 Habbema, 1988 De Charro, 1988, De kosten en effecten van harttransplantatie De Charro, 1988 Bonsel, 1989, Een ‘technology assessment’ van levertransplantatie; een onderzoek naar het Groningse levertransplantatieprogramma van 1977–1987, Ned Tijdschr Geneeskd, 133, 1406